ZYCUBO Drug Patent Profile
Which patents cover Zycubo, and what generic alternatives are available?
Zycubo is a drug marketed by Sentynl Theraps Inc and is included in one NDA.
The generic ingredient in ZYCUBO is copper histidinate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the copper histidinate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ZYCUBO?
- What are the global sales for ZYCUBO?
- What is Average Wholesale Price for ZYCUBO?
Summary for ZYCUBO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 74 |
| What excipients (inactive ingredients) are in ZYCUBO? | ZYCUBO excipients list |
| DailyMed Link: | ZYCUBO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZYCUBO
Generic Entry Date for ZYCUBO*:
Constraining patent/regulatory exclusivity:
TREATMENT OF MENKES DISEASE IN PEDIATRIC PATIENTS NDA:
Dosage:
POWDER;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for ZYCUBO
ZYCUBO is protected by zero US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZYCUBO is ⤷ Start Trial.
This potential generic entry date is based on TREATMENT OF MENKES DISEASE IN PEDIATRIC PATIENTS.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sentynl Theraps Inc | ZYCUBO | copper histidinate | POWDER;SUBCUTANEOUS | 211241-001 | Jan 12, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sentynl Theraps Inc | ZYCUBO | copper histidinate | POWDER;SUBCUTANEOUS | 211241-001 | Jan 12, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
